New Delhi: Molecular diagnostic company, Mylab Discovery Solutions on Wednesday announced that its ‘Pathocatch’ Covid-19 antigen rapid testing kit has received commercial approval from Indian Council of Medical Research (ICMR), making it the first Indian company to get the nod.
The indigenous kit is priced around INR 450 and will be available for orders immediately, said the Pune-based company in a release.
Also read: DCGI Approves Mylan in India for Tuberculosis Drug
“Mylab team is working really hard to fight this pandemic in every possible way. After bringing an affordable RT-PCR test to reduce dependence on foreign kits, we launched Compact XL to accelerate COVID-19 testing. Now, with the approval for an antigen testing kit, we will cover whole spectrum of COVID-19 testing and leave no stone unturned to fight this pandemic,” said Hasmukh Rawal, MD, Mylab Discovery Solutions.
According to the government guidelines, those who are found positive in the antigen test are considered positive, while those who get a negative result in antigen test are then tested with RT-PCR test for confirmation. As only suspected negative cases go for RT-PCR testing, this speed-up the process of testing and saves time and cost.
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
